Registered number: 09440413

CAPE HOLDINGS LIMITED

FOR THE YEAR ENDED 31 MARCH 2021

UNAUDITED DIRECTORS' REPORT AND FINANCIAL STATEMENTS

10/12/2021 COMPANIES HOUSE

COMPANY INFORMATION

Directors Mr J C Patel Jnr

Mr Inderdeep Ruprah Miss Jaspal Ruprah

Mr J C Patel

Company secretary Mr A R Patel

Registered number 09440413

Registered office 2 Peterwood Way

2 Peterwood Way Croydon Surrey CR0 4UQ

CONTENTS

	Page
Directors' Report	1
Profit and Loss Account	2
Statement of Comprehensive Income	2
Balance Sheet	3 - 4
Statement of Changes in Equity	5
Notes to the Financial Statements	6 - 21

DIRECTORS' REPORT FOR THE YEAR ENDED 31 MARCH 2021

The Directors present their report and the financial statements for the year ended 31 March 2021.

Principal activity

The principal activity of the company continued to be that of retail chemists and druggists.

Results and dividends

The profit for the year, after taxation, amounted to £198,991 (2020 - £120,583).

The Directors recommend a final dividend of £nil to be paid for the year (2020: £nil).

Directors

The Directors who served during the year were:

Mr J C Patel Jnr Mr Inderdeep Ruprah Miss Jaspal Ruprah Mr J C Patel

Post balance sheet events

There have been no significant events affecting the Company since the year ended 31 March 2021.

Small companies note

In preparing this report, the Directors have taken advantage of the small companies exemptions provided by section 415A of the Companies Act 2006.

This report was approved by the board and signed on its behalf.

Mr J C Patel Jnr

7.11

Director

Date: 29 November 2021

2 Peterwood Way

Croydon Surrey CR0 4UQ

PROFIT AND LOSS ACCOUNT FOR THE YEAR ENDED 31 MARCH 2021

	Note	2021 £	2020 £
Turnover	4	1,055,694	842,166
Cost of sales	•	(612,611)	(511,187)
Gross profit		443,083	330,979
Administrative expenses		(191,064)	(176,374)
Operating profit	5	252,019	154,605
Interest payable and similar expenses		(5,637)	(5,349)
Profit before tax		246,382	149,256
Tax on profit	7	(47,391)	(28,673)
Profit for the financial year		198,991	120,583

There were no recognised gains and losses for 2021 or 2020 other than those included in the profit and loss account.

STATEMENT OF COMPREHENSIVE INCOME FOR THE YEAR ENDED 31 MARCH 2021

	Note	2021 £	2020 £
Profit for the financial year	_	198,991	120,583
Other comprehensive income		-	-
Total comprehensive income for the year	-	198,991	120,583

The notes on pages 6 to 21 form part of these financial statements.

CAPE HOLDINGS LIMITED REGISTERED NUMBER:09440413

BALANCE SHEET AS AT 31 MARCH 2021

	Note		2021 £		2020 £
Fixed assets	.,,,,,		_		~
Intangible assets	8		453,588		458,363
Tangible assets	9		23,542		27,647
		-	477,130	-	486,010
Current assets					
Stocks	10	45,494		57,706	
Debtors: amounts falling due within one year	11	214,016		184,458	
Cash at bank and in hand	12	123,931		201,792	
		383,441	-	443,956	
Creditors: amounts falling due within one year	13	(256,329)		(477,701)	
Net current assets/(liabilities)			127,112		(33, 745)
Total assets less current liabilities		-	604,242	-	452,265
Creditors: amounts falling due after more than one year	14		(111,918)		(158,932)
Net assets			492,324	-	293,333
Capital and reserves					
Called up share capital	18		100		100
Profit and loss account	19		492,224		293,233
		-	492,324	-	293,333
		=		=	

CAPE HOLDINGS LIMITED REGISTERED NUMBER:09440413

BALANCE SHEET (CONTINUED) AS AT 31 MARCH 2021

The Directors consider that the Company is entitled to exemption from audit under section 479A of the Companies Act 2006.

The members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The Directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The Company's financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by:

Mr J C Patel Jnr

Director

7 M

Date: 29 November 2021

The notes on pages 6 to 21 form part of these financial statements.

STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 31 MARCH 2021

-		· 1
100	293,233	£ 293,333
-	198,991	198,991
-		-
-	198,991	198,991
-		-
100	492,224	492,324
	share capital £ 100	share capital loss account £ £ 100 293,233 - 198,991 198,991 198,991

STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 31 MARCH 2020

	Called up share capital £	Profit and loss account	Total equity £
At 1 April 2019	100	172,650	172,750
Comprehensive income for the year Profit for the year	-	120,583	120,583
Other comprehensive income for the year	-	-	-
Total comprehensive income for the year		120,583	120,583
Total transactions with owners	-	-	-
At 31 March 2020	100	293,233	293,333

The notes on pages 6 to 21 form part of these financial statements.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2021

1. General information

Cape Holdings Limited (the "Company") is a private company limited by shares and incorporated, domiciled and registered in England in the United Kingdom. The address of the registered office is given on the company information page. The nature of the company's operations and its principal activities are set out in the director's report on pages 1.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The functional currency of Cape Holdings Limited is considered to be pounds sterling because that is the currency of the primary economic environment in which the Company operates. The financial statements are also presented in pounds sterling and rounded to nearest £.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgement in applying the Company's accounting policies (see note 3).

The following principal accounting policies have been applied:

2.2 Financial reporting standard 102 - reduced disclosure exemptions

The company has taken advantage of the following disclosure exemptions in preparing these financial statements, as permitted by the FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland":

- the requirements of Section 7 Statement of Cash Flows;
- the requirements of Section 3 Financial Statement Presentation paragraph 3.17(d);
- the requirements of Section 11 Financial Instruments paragraphs 11.42, 11.44 to 11.45, 11.47, 11.48(a)(iii), 11.48(a)(iv), 11.48(b) and 11.48(c);
- the requirements of Section 12 Other Financial Instruments paragraphs 12.26 to 12.27, 12.29(a), 12.29(b) and 12.29A;
- the requirements of Section 26 Share-based Payment paragraphs 26.18(b), 26.19 to 26.21 and 26.23;
- the requirements of Section 33 Related Party Disclosures paragraph 33.7.

This information is included in the consolidated financial statements of Day Lewis Plc as at 31 March 2021 and these financial statements may be obtained from 2 Peterwood Way, Croydon, Surrey, CR0 4UQ.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2021

2. Accounting policies (continued)

2.3 Going concern

In assessing the validity of the going concern basis, and taking account of reasonably plausible downsides, the Directors have prepared financial forecasts for the period until 31 March 2023. In doing so they have considered the level of bank facilities available to the parent company and the Group, and its compliance with bank covenant tests both during the period and for the period ahead. In September 2020, the parent company refinanced its finance facility with 4 banks and now has in place an RCF facility of £125m until at least September 2023. The company is a party as an obligor to the cross guarantees with respect of the Group facilities.

Those forecasts are dependent on the company's immediate parent company, Stargazer Drug Stores Ltd, parent company Day Lewis Plc and a fellow subsidiary Day Lewis Medical Limited not seeking repayment of the amounts currently due to the group, which at 31 March 2021 amounted to £90,276. Stargazer Drug Stores Limited, Day Lewis Plc and Day Lewis Medical Limited has indicated that it does not intend to seek repayment of these amounts for the period covered by the forecasts. As with any company placing reliance on other group entities for financial support, the directors acknowledge that there can be no certainty that this support will continue although, at the date of approval of these financial statements, they have no reason to believe that it will not do so.

The Directors have assessed the impact of COVID-19 on the business has been limited. Based on their examination of its revenue sources, funding arrangements and operational soundness, they do not expect the impact of the current pandemic to present any risk of material degradation of the entity's revenue and margins within the next twelve months. The downside scenarios assume no growth in the next year and no additional funding from Government.

Having considered the Company's financial forecasts and investment and financing commitments for the year until 31 March 2023, the Directors believe the company has sufficient current and future cash reserves and facilities available for it to meet its liabilities including financing obligations for at least eighteen months from the date of signing of the financial statements.

Having considered the above, the Directors conclude that it is appropriate to adopt the going concern basis of accounting because there are no material uncertainties related to events or conditions that may cast significant doubt about the ability of the company to continue as a going concern. Thus they continue to adopt the going concern basis of accounting in preparing the annual financial statements.

2.4 Turnover

Turnover is recognised to the extent that it is probable that the economic benefits will flow to the Company and the turnover can be reliably measured. Turnover is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

2.5 Operating leases: the Company as lessee

Rentals paid under operating leases are charged to the Profit and Loss Account on a straight-line basis over the lease term.

Benefits received and receivable as an incentive to sign an operating lease are recognised on a straight-line basis over the lease term, unless another systematic basis is representative of the time pattern of the lessee's benefit from the use of the leased asset.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2021

2. Accounting policies (continued)

2.6 Finance costs

Finance costs are charged to the Profit and Loss Account over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

2.7 Borrowing costs

All borrowing costs are recognised in the Profit and Loss Account in the year in which they are incurred.

2.8 Current and deferred taxation

The tax expense for the year comprises current and deferred tax. Tax is recognised in the Profit and Loss Account except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the Balance Sheet date, except that:

- The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits;
- Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met; and
- Where they relate to timing differences in respect of interests in subsidiaries, associates, branches and joint ventures and the Company can control the reversal of the timing differences and such reversal is not considered probable in the foreseeable future.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2021

2. Accounting policies (continued)

2.9 Intangible assets

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses

All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years.

The estimated useful lives range as follows:

Retail pharmacy licence

100 years

2.10 Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives.

Depreciation is provided on the following basis:

Short-term leasehold property

over period of lease

Fixtures and fittings

15% reducing balance

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in the Profit and Loss Account.

2.11 Stocks

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first out basis. Work in progress and finished goods include labour and attributable overheads.

At each balance sheet date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in the Profit and Loss Account.

2.12 Debtors

Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2021

Accounting policies (continued)

2.13 Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

2.14 Creditors

Short term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

2.15 Provisions for liabilities

Provisions are made where an event has taken place that gives the Company a legal or constructive obligation that probably requires settlement by a transfer of economic benefit, and a reliable estimate can be made of the amount of the obligation.

Provisions are charged as an expense to the Profit and Loss Account in the year that the Company becomes aware of the obligation, and are measured at the best estimate at the Balance Sheet date of the expenditure required to settle the obligation, taking into account relevant risks and uncertainties.

When payments are eventually made, they are charged to the provision carried in the Balance Sheet.

2.16 Financial instruments

The Company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in ordinary shares.

Debt instruments (other than those wholly repayable or receivable within one year), including loans and other accounts receivable and payable, are initially measured at present value of the future cash flows and subsequently at amortised cost using the effective interest method. Debt instruments that are payable or receivable within one year, typically trade debtors and creditors, are measured, initially and subsequently, at the undiscounted amount of the cash or other consideration expected to be paid or received. However, if the arrangements of a short-term instrument constitute a financing transaction, like the payment of a trade debt deferred beyond normal business terms or in case of an out-right short-term loan that is not at market rate, the financial asset or liability is measured, initially at the present value of future cash flows discounted at a market rate of interest for a similar debt instrument and subsequently at amortised cost, unless it qualifies as a loan from a director in the case of a small company, or a public benefit entity concessionary loan.

Investments in non-derivative instruments that are equity to the issuer are measured:

- at fair value with changes recognised in the Profit and Loss Account if the shares are publicly traded or their fair value can otherwise be measured reliably;
- at cost less impairment for all other investments.

Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the Profit and Loss Account.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2021

2. Accounting policies (continued)

2.16 Financial instruments (continued)

For financial assets measured at amortised cost, the impairment loss is measured as the difference between an asset's carrying amount and the present value of estimated cash flows discounted at the asset's original effective interest rate. If a financial asset has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract.

For financial assets measured at cost less impairment, the impairment loss is measured as the difference between an asset's carrying amount and best estimate of the recoverable amount, which is an approximation of the amount that the Company would receive for the asset if it were to be sold at the balance sheet date.

Financial assets and liabilities are offset and the net amount reported in the Balance Sheet when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

2.17 Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2021

3. Judgements in applying accounting policies and key sources of estimation uncertainty

In the application of the company's accounting policies, which are described in note 2, the Directors are required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

Critical judgements in applying the company's accounting policies

The following are the critical judgements, apart from those involving estimations (which are dealt with separately below), that the Directors have made in the process of applying the company's accounting policies and that have the most significant effect on the amounts recognised in the financial statements.

Key source of estimation uncertainty - impairment of retail pharmacy licences

Determining whether retail pharmacy license is impaired requires an estimation of the value in use of the cash-generating units to which retail pharmacy license has been allocated. During this financial year the Directors have reassessed on what basis CGUs are formed to a higher sub regional level. The impairment value is based on applicable discount rate and turnaround plan for cash-generating units that may have been impaired. The carrying amount of retail pharmacy license at the balance sheet date was £458K (2020:£463K) after an impairment loss of £nil was recognised during the year 2021.

Key source of estimation uncertainty - useful life of retail pharmacy licences

The Directors believe that the right for dispensing UK NHS prescriptions, being the pharmacy licence which is attached to a particular pharmacy, has a continuing value. Such rights, conferred by the Department of Health as contracts to dispense prescriptions, are not generally granted to new pharmacies in the same locality. Consequently the Directors consider that the value of retail pharmacy licences have a long life of 100 years and therefore are amortised over that period.

4. Turnover

The whole of the turnover is attributable to be that of retail pharmacy.

Analysis of turnover by country of destination:

	2021 £	2020 £
United Kingdom	1,055,694	842,167
	1,055,694	842, 167

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2021

5.	Operating profit		
	The operating profit is stated after charging:		
		2021 £	2020
	Other operating lease rentals	19,500	18,048
6.	Employees		
	The average monthly number of employees, including the Directors, or	during the year was as fol	lows:
		2021 N o.	2020 No.
	Sales and distribution Pharmacist	3 1	3 1
		4	4
7.	Taxation		
		2021 £	2020 £
	Corporation tax		
	Current tax on profits for the year Adjustments in respect of previous periods	47,866 -	29,374 1
	Total current tax	47,866	 29,375
	Deferred tax		 -
	Origination and reversal of timing differences Changes to tax rates	(475) -	(447) (255)
	Total deferred tax	(475)	(702)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2021

7. Taxation (continued)

Factors affecting tax charge for the year

The tax assessed for the year is higher than (2020 - higher than) the standard rate of corporation tax in the UK of 19% (2020 - 19%). The differences are explained below:

	2021 £	2020 £
Profit on ordinary activities before tax	246,382	149,256
Profit on ordinary activities multiplied by standard rate of corporation tax in the UK of 19% (2020 - 19%) Effects of:	46,813	28,359
Expenses not deductible for tax purposes, other than goodwill amortisation and impairment	578	568
Adjustments to tax charge in respect of prior periods	-	1
Tax rate changes		(255)
Total tax charge for the year	47,391	28,673

Factors that may affect future tax charges

A reduction in the UK corporation tax rate from 19% to 17% (effective 1 April 2020) was substantively enacted on 6 September 2016. The March 2020 Budget announced that a rate of 19% would continue to apply with effect from 1 April 2020, and this change was substantively enacted on 17 March 2020. The UK deferred tax liability as at 2021 was calculated at 19% (2020: 17%).

An increase in the UK corporation rate from 19% to 25% (effective 1 April 2023) was substantively enacted on 24 May 2021. This will increase the company's future current tax charge accordingly and increase the deferred tax asset by £1,057.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2021

8. Intangible assets

	Retail pharmacy licences £
Cost	
At 1 April 2020	477,461
At 31 March 2021	477,461
Amortisation	
At 1 April 2020	19,098
Charge for the year on owned assets	4,775
At 31 March 2021	23,873
Net book value	
At 31 March 2021	453,588
At 31 March 2020	458,363

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2021

	Short-term leasehold property £	Fixtures and fittings	Total £
Cost or valuation			
At 1 April 2020	1,681	46,931	48,612
At 31 March 2021	1,681	46,931	48,612
Depreciation			-
At 1 April 2020	672	20,293	20,965
Charge for the year on owned assets	168	3,937	4,105
At 31 March 2021	840	24,230	25,070
Net book value			
At 31 March 2021	841	22,701	23,542

10. Stocks

At 31 March 2020

9.

Tangible fixed assets

	2021 £	2020 £
Finished goods and goods for resale	45,494	57,706
	45,494	57,706

1,009

26,638

Stock recognised in cost of sales during the year as an expense was £612,611 (2020 - £511,187).

An impairment loss of £nil (2020 - £nil) was recognised in cost of sales against stock during the year due to slow-moving and obsolete stock.

27,647

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2021

11.	Debtors		
		2021 £	2020 £
	Trade debtors	181,392	150,248
	Amounts owed by group undertakings	-	432
	Other debtors	10,729	17,288
	Prepayments and accrued income	18,548	13,618
	Deferred taxation	3,347	2,872
		214,016	184,458
12.	Cash and cash equivalents		
		2021 £	2020 £
	Cash at bank and in hand	123,931	201,792
		123,931	201,792
13.	Creditors: Amounts falling due within one year		
		2021 £	2020 £
	Bank loans	41,229	41,229
	Trade creditors	73,801	78,959
	Amounts owed to group undertakings	47,817	207,913
	Corporation tax	56,461	<i>37,969</i>
	Other taxation and social security	2,302	1,952
	Other creditors	4,307	104,027
	Accruals and deferred income	3,033	5,652
	Government grants payable	27,379	-
		256,329	477,701

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2021

14. Creditors: Amounts falling due after more than one y	14.	Creditors:	Amounts	falling due	after more	than one	vear
--	-----	------------	---------	-------------	------------	----------	------

	2021 £	2020 £
Bank loans	111,918	158,932
	111,918	158,932

Bank loan is secured by way of a first legal charge on leasehold property owned by the company and debenture consisting of fixed and floating charges over the company's assets. The bank loan has a maturity date of May 2025. The loan bears fixed interest rate of 2.46% per annum until May 2021.

15. Loans

Analysis of the maturity of loans is given below:

2021 £	2020 £
Amounts falling due within one year	
Bank loans 41,229	41,229
41,229	41,229
Amounts falling due 1-2 years	
Bank loans 41,229	41,229
41,229	41,229
Amounts falling due 2-5 years	
Bank loans 70,689	117,703
70,689	117,703
153,147	200, 161

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2021

16.	Financial instruments		
		2021 £	2020 £
	Financial assets	_	~
	Financial assets measured at fair value	123,931	201,792
	Financial assets measured at amortised cost	192,121	167,968
		316,052	369,760
	Financial liabilities		
	Financial liabilities measured at amortised cost	(365,214)	(630,981)
17.	Deferred taxation		
		2021 £	2020 £
	At beginning of year	2,872	2,170
	Charged to profit or loss	475	702
	At end of year	3,347	2,872
	The deferred tax asset is made up as follows:		
		2021 £	2020 £
	Accelerated capital allowances	(1,232)	(831)
	Other timing differences	43	74
	Deferred tax on retail pharmacy licences	4,536	3,629
		3,347	2,872
18.	Share capital		
	Allacka to a Dad on and Cillian and	2021 £	2020 £
	Allotted, called up and fully paid 100 (2020 - 100) Ordinary shares of £1.00 each	100	100

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2021

19. Reserves

Profit and loss account

The profit and loss reserve represents cumulative profits or losses, including dividends paid and other adjustments.

20. Commitments under operating leases

At 31 March 2021 the Company had future minimum lease payments due under non-cancellable operating leases for each of the following periods:

	2021 £	2020 £
Ending not later than 1 year	18,000	18,000
Ending later than 1 year and not later than 5 years	71,014	72,000
Ending later than 5 years	-	17,014
	89,014	107,014
		

21. Related party transactions

A total of £113,596 (2020: £130,280) worth of expenses paid by the Day Lewis Plc, a parent company on behalf of the company. The company recharged £nil (2020: £nil) worth of expenses paid on behalf of the Day Lewis Plc. As at 31 March 2021 the company owed £2,238 (2020: £56,275) to Day Lewis Plc.

During the year the company made purchases totalling £288,006 (2020: £246,178) from and recharged expenses of £nil (2020: £nil) paid on behalf of the Day Lewis Medical Limited, a fellow subsidiary of the company's parent company Day Lewis Plc. As at 31 March 2021 Day Lewis Medical Limited owed £45,002 (2020: £48,929) to the company.

The company recharged £nil (2020: £nil) worth of expenses paid on behalf of ABC Drug Stores Limited, a fellow subsidiary of the company's parent company Day Lewis Plc. ABC Drug Stores Limited paid expenses of £nil (2020: £nil) on behalf of the company. As at 31 March 2021 ABC Drug Stores Limited owed £nil (2020: £432) to the company.

During the year £nil (2020: £nil) funds made available to the company by Stargazer Drug Stores Limited, a immediate parent company. As at 31 March 2021 the company owed £102,709 (2020: £102,709) to Stargazer Drug Stores Limited.

During the year £nil (2020: £nil) funds made available to the company by I Pill Investments Limited, Mr Inderdeep Ruprah, a director, has material interest in the company. As at 31 March 2021 the company owed £nil (2020: £100,376) to I Pill Investments Limited.

The company purchased goods of £12,565 (2020: £nil) from Eaststone Limited, a company in which the executors of the KCTP Will Trust has a controlling interest. At the balance sheet date £2,241 (2020: £nil) was payable to Eaststone Limited.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2021

22. Controlling party

The company's parent company is Stargazer Drug Stores Limited, a company registered in England and Wales.

Stargazer Drug Stores Limited is a subsidiary of Day Lewis Plc, a company registered in England and Wales. It prepares group accounts which are available at Day Lewis House, 2 Peterwood Way, Croydon, Surrey, CR0 4UQ.

The ultimate parent company is Day Lewis Holdings Limited, a company registered in Cyprus and controlled by the KCTP Will Trust.